Literature DB >> 19415471

Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.

Nashwa El-Gendy1, Cory Berkland.   

Abstract

PURPOSE: To develop an aerosol system for efficient local lung delivery of chemotherapeutics where nanotechnology holds tremendous potential for developing more valuable cancer therapies. Concurrently, aerosolized chemotherapy is generating interest as a means to treat certain types of lung cancer more effectively with less systemic exposure to the compound.
METHODS: Nanoparticles of the potent anticancer drug, paclitaxel, were controllably assembled to form low density microparticles directly after preparation of the nanoparticle suspension. The amino acid, L-leucine, was used as a colloid destabilizer to drive the assembly of paclitaxel nanoparticles. A combination chemotherapy aerosol was formed by assembling the paclitaxel nanoparticles in the presence of cisplatin in solution.
RESULTS: Freeze-dried powders of the combination chemotherapy possessed desirable aerodynamic properties for inhalation. In addition, the dissolution rates of dried nanoparticle agglomerate formulations (approximately 60% to 66% after 8 h) were significantly faster than that of micronized paclitaxel powder as received (approximately 18% after 8 h). Interestingly, the presence of the water soluble cisplatin accelerated the dissolution of paclitaxel.
CONCLUSIONS: Nanoparticle agglomerates of paclitaxel alone or in combination with cisplatin may serve as effective chemotherapeutic dry powder aerosols to enable regional treatment of certain lung cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415471      PMCID: PMC4123657          DOI: 10.1007/s11095-009-9886-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  58 in total

1.  Formulation and physical characterization of large porous particles for inhalation.

Authors:  R Vanbever; J D Mintzes; J Wang; J Nice; D Chen; R Batycky; R Langer; D A Edwards
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

2.  Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.

Authors:  S Pham; T S Wiedmann
Journal:  J Pharm Sci       Date:  2001-01       Impact factor: 3.534

3.  PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties.

Authors:  K Avgoustakis; A Beletsi; Z Panagi; P Klepetsanis; A G Karydas; D S Ithakissios
Journal:  J Control Release       Date:  2002-02-19       Impact factor: 9.776

Review 4.  Novel alternative methods for the delivery of drugs for the treatment of asthma.

Authors:  Hak Kim Chan; Nora Y K Chew
Journal:  Adv Drug Deliv Rev       Date:  2003-07-18       Impact factor: 15.470

5.  Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.

Authors:  R Rosell; U Gatzemeier; D C Betticher; U Keppler; H N Macha; R Pirker; P Berthet; J L Breau; P Lianes; M Nicholson; A Ardizzoni; A Chemaissani; J Bogaerts; G Gallant
Journal:  Ann Oncol       Date:  2002-10       Impact factor: 32.976

6.  Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance.

Authors:  C Bosquillon; C Lombry; V Préat; R Vanbever
Journal:  J Control Release       Date:  2001-02-23       Impact factor: 9.776

7.  Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.

Authors:  K Yamamoto; Y Kikuchi; K Kudoh; J Hirata; T Kita; I Nagata
Journal:  Jpn J Clin Oncol       Date:  2000-10       Impact factor: 3.019

8.  Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1).

Authors:  Nagesh Bandi; Uday B Kompella
Journal:  Eur J Pharmacol       Date:  2002-02-15       Impact factor: 4.432

Review 9.  Paclitaxel and its formulations.

Authors:  Anil K Singla; Alka Garg; Deepika Aggarwal
Journal:  Int J Pharm       Date:  2002-03-20       Impact factor: 5.875

10.  Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing".

Authors:  P M Young; D Cocconi; P Colombo; R Bettini; R Price; D F Steele; M J Tobyn
Journal:  J Pharm Pharmacol       Date:  2002-10       Impact factor: 3.765

View more
  14 in total

1.  Building membrane emulsification into pulmonary drug delivery and targeting.

Authors:  Decai Bao; Yanjun Zhao
Journal:  Pharm Res       Date:  2010-08-12       Impact factor: 4.200

2.  Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.

Authors:  Philip Chi Lip Kwok; Amolnat Tunsirikongkon; William Glover; Hak-Kim Chan
Journal:  Pharm Res       Date:  2010-12-07       Impact factor: 4.200

Review 3.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

Review 4.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

5.  Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent.

Authors:  Nashwa El-Gendy; Kristin L Aillon; Cory Berkland
Journal:  Int J Pharm       Date:  2010-03-07       Impact factor: 5.875

6.  Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization.

Authors:  Kristin L Aillon; Nashwa El-Gendy; Connor Dennis; Jeffrey P Norenberg; Jacob McDonald; Cory Berkland
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 7.  Novel Approaches for the Treatment of Pulmonary Tuberculosis.

Authors:  Zhi Ming Tan; Gui Ping Lai; Manisha Pandey; Teerapol Srichana; Mallikarjuna Rao Pichika; Bapi Gorain; Subrat Kumar Bhattamishra; Hira Choudhury
Journal:  Pharmaceutics       Date:  2020-12-10       Impact factor: 6.321

Review 8.  Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.

Authors:  Andrew M Shen; Tamara Minko
Journal:  J Control Release       Date:  2020-07-16       Impact factor: 9.776

9.  Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols.

Authors:  Nashwa El-Gendy; Warangkana Pornputtapitak; Cory Berkland
Journal:  Eur J Pharm Sci       Date:  2011-09-21       Impact factor: 4.384

10.  Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.

Authors:  Mohammed M Mehanna; Salma M Mohyeldin; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2019-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.